Karyopharm Enters Distribution Agreement for XPOVIO in Israel

- February 11th, 2020

Karyopharm and Promedico entered into a distribution agreement for the commercialization of XPOVIO in Israel and the Palestinian Authority.

Karyopharm Therapeutics (NASDAQ:KPTI) and Promedico entered into an exclusive distribution agreement for the commercialization of XPOVIO in Israel and the Palestinian Authority.

As quoted in the press release:

Under the terms of the agreement, Karyopharm will receive certain prespecified payments and is eligible to receive additional payments if prespecified regulatory and commercial milestones are achieved by Promedico, a fully-owned Neopharm LTD company. Karyopharm is also eligible to receive double-digit royalties on future net sales of XPOVIO in the covered territory. In exchange, Promedico will receive exclusive rights to commercialize XPOVIO in the covered territory and is responsible for all regulatory filings and obligations required for registering XPOVIO. Karyopharm has retained exclusive production rights and will supply finished product for commercial use in the covered territory.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply